Published 2022
| Version v1
Publication
Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer
Description
Second and third-generation ALK inhibitors (ALKIs) have been recently approved for ALK-translocated lung cancer treatment, improving - and expanding - the first-line scenario.
Additional details
Identifiers
- URL
- http://hdl.handle.net/11567/1091134
- URN
- urn:oai:iris.unige.it:11567/1091134
Origin repository
- Origin repository
- UNIGE